Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study to Assess the Efficacy of Combined Tafasitamab and Rituximab in Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder

NCT05786040 is registered in ClinicalTrials.gov with Timothy Voorhees as lead sponsor.

NCT NCT05786040
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05786040 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study to Assess the Efficacy of Combined Tafasitamab and Rituximab in Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder
Lead sponsor
Timothy Voorhees
Phase
Phase 2
Overall status
Recruiting
Start date
March 23, 2023
Completion date
December 31, 2027
Enrollment
28 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

monomorphic b-cell post-transplant lymphoproliferative disorder, polymorphic post-transplant lymphoproliferative disorder